US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US20170166655A1
(en)
*
|
2004-03-26 |
2017-06-15 |
Xencor, Inc. |
Novel immunoglobulin variants
|
CN102746404B
(zh)
|
2004-11-12 |
2016-01-20 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
RU2607014C2
(ru)
|
2011-03-29 |
2017-01-10 |
Рош Гликарт Аг |
Fc варианты антитела
|
EP2699256B1
(en)
|
2011-04-21 |
2017-09-27 |
The Regents of the University of Colorado, a body corporate |
Compositions and methods for the treatment of neuromyelitis optica
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
US10400029B2
(en)
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
CN103917563A
(zh)
|
2011-06-28 |
2014-07-09 |
英伊布里克斯有限责任公司 |
丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
CA2860600C
(en)
*
|
2012-02-15 |
2022-07-26 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
AR092027A1
(es)
*
|
2012-07-13 |
2015-03-18 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
|
JP6388581B2
(ja)
*
|
2012-08-02 |
2018-09-12 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
単量体および多量体分子を生産するための方法およびその使用
|
ES2848732T3
(es)
|
2012-08-07 |
2021-08-11 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
PE20150645A1
(es)
|
2012-08-08 |
2015-05-11 |
Roche Glycart Ag |
Proteinas de fusion de interleuquina 10 y usos de las mismas
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
RU2015117393A
(ru)
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
EP3620473A1
(en)
|
2013-01-14 |
2020-03-11 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
WO2014122144A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
SG11201506132PA
(en)
*
|
2013-02-06 |
2015-09-29 |
Inhibrx Llc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
WO2014131711A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
NZ708182A
(en)
|
2013-02-26 |
2019-08-30 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
ES2933558T3
(es)
|
2013-03-13 |
2023-02-10 |
Genzyme Corp |
Proteínas de fusión que comprenden porciones de unión a PDGF y VEGF y métodos de uso de las mismas
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
JP6427552B2
(ja)
|
2013-03-15 |
2018-11-21 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
フラビウイルス中和抗体およびその使用方法
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
EP2992010B1
(en)
*
|
2013-04-29 |
2021-03-24 |
F.Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
UA118029C2
(uk)
|
2013-04-29 |
2018-11-12 |
Ф. Хоффманн-Ля Рош Аг |
Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
|
PL3594240T3
(pl)
*
|
2013-05-20 |
2024-04-02 |
F. Hoffmann-La Roche Ag |
Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
|
AU2014273817B2
(en)
|
2013-05-31 |
2019-03-14 |
Zymeworks Bc Inc. |
Heteromultimers with reduced or silenced effector function
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
BR112016005408B1
(pt)
|
2013-09-13 |
2023-03-21 |
Beigene Switzerland Gmbh |
Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral
|
CA2930307A1
(en)
|
2013-11-13 |
2015-05-21 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
CA2941958A1
(en)
*
|
2013-12-10 |
2015-06-18 |
F. Hoffmann-La Roche Ag |
Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure
|
WO2015095392A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
CA2929149A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Improved recombinant polypeptide production methods
|
PL3092251T3
(pl)
*
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
EP3094648A1
(en)
|
2014-01-15 |
2016-11-23 |
F. Hoffmann-La Roche AG |
Fc-region variants with improved protein a-binding
|
CR20160333A
(es)
*
|
2014-02-06 |
2016-09-05 |
F Hoffman-La Roche Ag |
Proteinas de fusión de interleucina-2 y usos de las mismas
|
MX2016010174A
(es)
*
|
2014-02-06 |
2016-11-15 |
Hoffmann La Roche |
Proteinas de fusion de interleucina-10 y usos de las mismas.
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
CN111410691B
(zh)
|
2014-03-28 |
2024-02-13 |
Xencor公司 |
结合至cd38和cd3的双特异性抗体
|
EP3160505A4
(en)
|
2014-07-03 |
2018-01-24 |
BeiGene, Ltd. |
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
|
JP6986965B2
(ja)
|
2014-07-22 |
2021-12-22 |
アポロミクス インコーポレイテッド |
抗pd−1抗体
|
MX2017001556A
(es)
|
2014-08-04 |
2017-05-15 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t.
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
WO2016022630A1
(en)
|
2014-08-05 |
2016-02-11 |
Jiping Zha |
Anti-pd-l1 antibodies
|
TW201625688A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
經半胱胺酸改造之抗體及接合物
|
CN114106185A
(zh)
|
2014-09-12 |
2022-03-01 |
基因泰克公司 |
抗her2抗体和免疫缀合物
|
MX2017003022A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados.
|
WO2016044396A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
US9938522B2
(en)
|
2014-09-25 |
2018-04-10 |
Genewiz, Inc. |
High throughput sequencing of end regions of long linear DNAs
|
CA2963692A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
IL308589A
(en)
*
|
2014-10-27 |
2024-01-01 |
Inhibrx Inc |
Serpin-fused polypeptides and methods of using them
|
US20160130324A1
(en)
*
|
2014-10-31 |
2016-05-12 |
Shire Human Genetic Therapies, Inc. |
C1 Inhibitor Fusion Proteins and Uses Thereof
|
BR112017004810A2
(pt)
*
|
2014-11-05 |
2017-12-12 |
Hoffmann La Roche |
imunoensaio
|
DK3215528T3
(da)
|
2014-11-06 |
2019-10-07 |
Hoffmann La Roche |
Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
|
RS60201B1
(sr)
|
2014-11-14 |
2020-06-30 |
Hoffmann La Roche |
Antigen vezujući molekuli koji sadrže trimer liganda familije tnf
|
KR102614189B1
(ko)
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
LT3789402T
(lt)
|
2014-11-20 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
WO2016086196A2
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
LT3223845T
(lt)
|
2014-11-26 |
2021-08-25 |
Xencor, Inc. |
Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20
|
WO2016082044A1
(en)
|
2014-11-27 |
2016-06-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
KR20230137502A
(ko)
|
2014-12-19 |
2023-10-04 |
레제네상스 비.브이. |
인간 c6에 결합하는 항체 및 이의 용도
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
MA41459A
(fr)
|
2015-02-03 |
2017-12-12 |
Als Therapy Development Inst |
Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
JP6957355B2
(ja)
|
2015-03-17 |
2021-11-02 |
エイジェンシー フォー サイエンス,テクノロジー アンド リサーチ |
血清型交差反応性デング熱中和抗体及びその使用
|
JP6773679B2
(ja)
|
2015-03-30 |
2020-10-21 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Fcガンマ受容体に対する結合が低下した重鎖定常領域
|
CN114751989A
(zh)
*
|
2015-03-31 |
2022-07-15 |
豪夫迈·罗氏有限公司 |
包含三聚体tnf家族配体的抗原结合分子
|
AU2016246695A1
(en)
*
|
2015-04-07 |
2017-10-26 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
CA2984794A1
(en)
|
2015-05-07 |
2016-11-10 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
WO2016183104A1
(en)
|
2015-05-11 |
2016-11-17 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
AU2016280102B2
(en)
|
2015-06-16 |
2022-06-16 |
Genentech, Inc. |
Humanized and affinity matured antibodies to FcRH5 and methods of use
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
CA2986592A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
CA2985718A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies with tailored affinity
|
EP3313887A2
(en)
*
|
2015-06-26 |
2018-05-02 |
MAB Discovery GmbH |
Monoclonal anti-il-1racp antibodies
|
BR112017028353A2
(pt)
|
2015-06-29 |
2018-09-04 |
The Rockfeller University |
anticorpos para cd40 com atividade agonista melhorada
|
RS60030B1
(sr)
|
2015-08-03 |
2020-04-30 |
Engmab Sarl |
Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma)
|
SI3331902T1
(sl)
|
2015-08-07 |
2021-09-30 |
ALX Oncology Inc. |
Konstrukti z domeno SIRP-alfa ali njegove različice
|
CN113956358A
(zh)
|
2015-09-25 |
2022-01-21 |
豪夫迈·罗氏有限公司 |
抗tigit抗体和使用方法
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
WO2017055389A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
CN108026179A
(zh)
|
2015-10-02 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
JP6937746B2
(ja)
|
2015-10-02 |
2021-09-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗cd19×cd3t細胞活性化抗原結合分子
|
AU2016329126B2
(en)
|
2015-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for PD1 and TIM3
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
PE20231655A1
(es)
|
2015-10-02 |
2023-10-17 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
|
SI3356404T1
(sl)
*
|
2015-10-02 |
2021-11-30 |
F. Hoffmann-La Roche Ag |
Protitelesa proti PD1 in postopki uporabe
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
AU2016330807B2
(en)
*
|
2015-10-02 |
2023-08-10 |
F. Hoffmann-La Roche Ag |
Anti-human CD19 antibodies with high affinity
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
CN108602887B
(zh)
|
2015-10-02 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
对共刺激性tnf受体特异性的双特异性抗体
|
JP2018533930A
(ja)
|
2015-10-02 |
2018-11-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性t細胞活性化抗原結合分子
|
JP7074665B2
(ja)
|
2015-10-07 |
2022-05-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体に対する四価の二重特異性抗体発明の分野
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
AU2016350701B2
(en)
|
2015-11-02 |
2021-08-19 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
EP3165536A1
(en)
*
|
2015-11-09 |
2017-05-10 |
Ludwig-Maximilians-Universität München |
Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
|
EP3383430A4
(en)
|
2015-12-02 |
2019-12-18 |
Agenus Inc. |
ANTIBODIES AND METHOD FOR USE THEREOF
|
US10227410B2
(en)
|
2015-12-07 |
2019-03-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
EP3387439B1
(en)
*
|
2015-12-09 |
2020-02-26 |
H. Hoffnabb-La Roche Ag |
Direct affinity measurement of human igg1 binding multimeric antigens
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
EP4026848A1
(en)
|
2015-12-09 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing the cytokine release syndrome
|
CN106939047B
(zh)
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
EA201891299A1
(ru)
|
2016-01-08 |
2019-01-31 |
Аимм Терапьютикс Б.В. |
Терапевтические антитела к cd9
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
CN108699155B
(zh)
*
|
2016-03-01 |
2023-03-21 |
豪夫迈·罗氏有限公司 |
具有改变的细胞死亡诱导的奥滨尤妥珠单抗变体
|
HUE061946T2
(hu)
|
2016-03-22 |
2023-09-28 |
Hoffmann La Roche |
Proteáz-aktivált T-sejt bispecifikus molekulák
|
PT3433280T
(pt)
|
2016-03-22 |
2023-06-15 |
Hoffmann La Roche |
Moléculas biespecíficas das células t ativadas pela protease
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
RU2018139339A
(ru)
|
2016-04-22 |
2020-05-22 |
Эллигейтор Биосайенс Аб |
Новые биспецифические полипептиды против cd137
|
EP3241845A1
(en)
|
2016-05-06 |
2017-11-08 |
MAB Discovery GmbH |
Humanized anti-il-1r3 antibodies
|
CN109071652B
(zh)
*
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
CN109152843A
(zh)
|
2016-05-20 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
JP7012668B2
(ja)
|
2016-06-12 |
2022-02-14 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
|
US10787518B2
(en)
|
2016-06-14 |
2020-09-29 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
GB201611530D0
(en)
|
2016-07-01 |
2016-08-17 |
Alligator Bioscience Ab |
Novel polypeptides
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
RU2656181C1
(ru)
*
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
WO2018052556A1
(en)
|
2016-08-02 |
2018-03-22 |
Visterra, Inc. |
Engineered polypeptides and uses thereof
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
CN110267977A
(zh)
|
2016-08-10 |
2019-09-20 |
亚洲大学校产学协力团 |
细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物
|
CN109689111B
(zh)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
吡咯并苯并二氮杂䓬前药及其抗体缀合物
|
CN110087680B
(zh)
|
2016-08-19 |
2024-03-19 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
WO2018036852A1
(en)
|
2016-08-25 |
2018-03-01 |
F. Hoffmann-La Roche Ag |
Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018060301A1
(en)
|
2016-09-30 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against cd3
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
AU2017342560B2
(en)
|
2016-10-14 |
2022-03-17 |
Xencor, Inc. |
IL15/IL15Ralpha heterodimeric Fc-fusion proteins
|
EP3535291A1
(en)
|
2016-11-01 |
2019-09-11 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
CN110167964B
(zh)
|
2016-11-02 |
2023-12-01 |
百时美施贵宝公司 |
组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
|
EP3538152A4
(en)
|
2016-11-09 |
2020-09-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
TW201829463A
(zh)
*
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
MA50948A
(fr)
|
2016-12-07 |
2020-10-14 |
Agenus Inc |
Anticorps et procédés d'utilisation de ceux-ci
|
BR112019011199A2
(pt)
|
2016-12-12 |
2019-10-08 |
Genentech Inc |
método para tratar um indivíduo que tem um câncer de próstata e kits
|
TWI829628B
(zh)
|
2016-12-19 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
與靶向4-1bb (cd137)促效劑併用之組合療法
|
AU2017384126A1
(en)
|
2016-12-20 |
2019-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
|
EP3558360A1
(en)
|
2016-12-22 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
|
CR20190309A
(es)
|
2017-01-03 |
2019-08-21 |
Hoffmann La Roche |
Moleculas de unión de3 antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb
|
WO2018129384A1
(en)
|
2017-01-06 |
2018-07-12 |
Avidity Biosciences Llc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
CN110325210A
(zh)
|
2017-01-11 |
2019-10-11 |
小利兰·斯坦福大学托管委员会 |
Rspo替代物分子
|
TWI787230B
(zh)
*
|
2017-01-20 |
2022-12-21 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
CA3050133A1
(en)
|
2017-01-26 |
2018-08-02 |
Surrozen, Inc. |
Tissue-specific wnt signal enhancing molecules and uses thereof
|
PE20200152A1
(es)
|
2017-03-27 |
2020-01-17 |
Hoffmann La Roche |
Receptores de union a antigeno mejorados
|
CR20190431A
(es)
|
2017-03-27 |
2019-11-01 |
Hoffmann La Roche |
Formatos mejorados de receptor de unión a antígeno
|
JP7196094B2
(ja)
|
2017-03-29 |
2022-12-26 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体のための二重特異性抗原結合分子
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
JP7205995B2
(ja)
|
2017-03-29 |
2023-01-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激性tnf受容体に対する二重特異性抗原結合分子
|
ES2928718T3
(es)
|
2017-04-03 |
2022-11-22 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15
|
SG11201909218RA
(en)
|
2017-04-03 |
2019-11-28 |
Hoffmann La Roche |
Antibodies binding to steap-1
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
CN110402255B
(zh)
|
2017-04-04 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
|
KR102408873B1
(ko)
|
2017-04-05 |
2022-06-15 |
에프. 호프만-라 로슈 아게 |
Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
|
DK3606954T3
(en)
*
|
2017-04-05 |
2022-09-26 |
Hoffmann La Roche |
Anti-LAG3-antistoffer
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
AU2018250875A1
(en)
|
2017-04-13 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
|
AU2018251993A1
(en)
|
2017-04-14 |
2019-10-24 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
EP3610010A4
(en)
*
|
2017-04-14 |
2021-02-24 |
Kodiak Sciences Inc. |
COMPLEMENT D-FACTOR ANTAGONIST ANTIBODIES AND THEIR CONJUGATES
|
WO2018201014A1
(en)
|
2017-04-28 |
2018-11-01 |
Five Prime Therapeutics, Inc. |
Methods of treatment with cd80 extracellular domain polypeptides
|
EP3401332A1
(en)
|
2017-05-08 |
2018-11-14 |
MAB Discovery GmbH |
Anti-il-1r3 antibodies for use in inflammatory conditions
|
CN117843789A
(zh)
|
2017-05-24 |
2024-04-09 |
Als治疗发展学会 |
治疗性抗cd40配体抗体
|
US11597764B2
(en)
|
2017-06-15 |
2023-03-07 |
Memorial Sloan Kettering Cancer Center |
Anti-L1-CAM antibodies and uses thereof
|
CA3065553A1
(en)
|
2017-06-18 |
2018-12-27 |
Kindred Biosciences, Inc. |
Il17a antibodies and antagonists for veterinary use
|
CN110831969B
(zh)
|
2017-06-20 |
2024-06-21 |
安进公司 |
使用抑胃肽受体(gipr)结合蛋白与glp-1激动剂的组合治疗或改善代谢障碍的方法
|
WO2019001417A1
(en)
|
2017-06-26 |
2019-01-03 |
Beigene, Ltd. |
IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
|
JP2020529832A
(ja)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質
|
IL272103B1
(en)
|
2017-07-20 |
2024-06-01 |
Aptevo Res & Development Llc |
Antigen-binding proteins that bind to 5T4 and 4-1BB, as well as compositions and methods for treating cancer related to them
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
CN111094352A
(zh)
|
2017-08-25 |
2020-05-01 |
戊瑞治疗有限公司 |
B7-h4抗体及其使用方法
|
AU2018323470A1
(en)
|
2017-08-28 |
2020-03-19 |
Angiex, Inc. |
Anti-TM4SF1 antibodies and methods of using same
|
US20190100587A1
(en)
*
|
2017-10-02 |
2019-04-04 |
Covagen Ag |
IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
|
US11472889B2
(en)
|
2017-10-14 |
2022-10-18 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
US20210324108A1
(en)
|
2017-11-01 |
2021-10-21 |
Hoffmann-La Roche Inc. |
Bispecific 2+1 contorsbodies
|
BR112020007630A2
(pt)
|
2017-11-01 |
2020-11-17 |
F. Hoffmann-La Roche Ag |
anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40
|
WO2019086499A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Novel tnf family ligand trimer-containing antigen binding molecules
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
GEP20237565B
(en)
|
2017-11-17 |
2023-11-10 |
Merck Sharp & Dohme Llc |
Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
MX2020005860A
(es)
|
2017-12-06 |
2020-09-09 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica.
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
CN111247429A
(zh)
*
|
2017-12-21 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
用于新颖抗原结合模块的特异性测试的通用报告细胞测定法
|
KR102575787B1
(ko)
|
2017-12-21 |
2023-09-08 |
에프. 호프만-라 로슈 아게 |
Hla-a2/wt1에 결합하는 항체
|
EP3731865A1
(en)
|
2017-12-29 |
2020-11-04 |
F. Hoffmann-La Roche AG |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
CN108218998A
(zh)
*
|
2017-12-31 |
2018-06-29 |
武汉班科生物技术股份有限公司 |
一种突变型人源IgG的Fc片段及其制备方法与应用
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
US20210107988A1
(en)
|
2018-01-24 |
2021-04-15 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
JP2021511782A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
安定化された免疫グロブリンドメイン
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
KR20200118065A
(ko)
|
2018-02-08 |
2020-10-14 |
제넨테크, 인크. |
이중특이적 항원-결합 분자 및 이의 사용 방법
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
WO2019165077A1
(en)
|
2018-02-21 |
2019-08-29 |
Five Prime Therapeutics, Inc. |
B7-h4 antibody formulations
|
AU2019226009A1
(en)
|
2018-02-21 |
2020-09-03 |
Five Prime Therapeutics, Inc. |
B7-H4 antibody dosing regimens
|
WO2019165434A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
AU2019228600A1
(en)
|
2018-03-02 |
2020-09-24 |
Five Prime Therapeutics, Inc. |
B7-H4 antibodies and methods of use thereof
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
CA3092002A1
(en)
|
2018-03-13 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
RS64690B1
(sr)
|
2018-03-13 |
2023-11-30 |
Zymeworks Bc Inc |
Konjugati biparatopskog anti-her2 antitela i leka i postupci za njihovu upotrebu
|
CN110305217B
(zh)
*
|
2018-03-27 |
2022-03-29 |
广州爱思迈生物医药科技有限公司 |
双特异性抗体及其应用
|
SG11202009542PA
(en)
|
2018-03-29 |
2020-10-29 |
Genentech Inc |
Modulating lactogenic activity in mammalian cells
|
EP3774798A1
(en)
|
2018-04-02 |
2021-02-17 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
CR20200459A
(es)
|
2018-04-13 |
2020-11-11 |
Hoffmann La Roche |
Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
US11524991B2
(en)
|
2018-04-18 |
2022-12-13 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
CN112437777A
(zh)
|
2018-04-18 |
2021-03-02 |
Xencor股份有限公司 |
包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
|
SG11202010601VA
(en)
|
2018-05-03 |
2020-11-27 |
Genmab Bv |
Antibody variant combinations and uses thereof
|
SG11202011703VA
(en)
|
2018-05-25 |
2020-12-30 |
Silverback Therapeutics Inc |
Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof
|
AU2019283314A1
(en)
|
2018-06-05 |
2021-01-07 |
GammaDelta Therapeutics Limited |
BTNL3/8 targeting constructs for delivery of payloads to the gastrointestinal system
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
EP3818082A1
(en)
|
2018-07-04 |
2021-05-12 |
F. Hoffmann-La Roche AG |
Novel bispecific agonistic 4-1bb antigen binding molecules
|
US11590223B2
(en)
|
2018-08-31 |
2023-02-28 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
CA3111784A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Methods and compositions for the treatment of disease with immune stimulatory conjugates
|
CN113166113A
(zh)
|
2018-09-12 |
2021-07-23 |
希沃尔拜克治疗公司 |
取代的苯并氮杂䓬化合物、缀合物及其用途
|
US20210277121A1
(en)
*
|
2018-09-29 |
2021-09-09 |
Mab-Legend Biotech Co., Ltd. |
Dual targeting antigen binding molecule
|
EP3861025A1
(en)
|
2018-10-01 |
2021-08-11 |
F. Hoffmann-La Roche AG |
Bispecific antigen binding molecules with trivalent binding to cd40
|
AU2019355252A1
(en)
|
2018-10-01 |
2021-04-01 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-FAP clone 212
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
WO2020081497A1
(en)
|
2018-10-15 |
2020-04-23 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
WO2020086758A1
(en)
|
2018-10-23 |
2020-04-30 |
Dragonfly Therapeutics, Inc. |
Heterodimeric fc-fused proteins
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
KR20210087472A
(ko)
*
|
2018-11-01 |
2021-07-12 |
산동 뉴 타임 파마슈티칼 코., 리미티드. |
이중 특이성 항체 및 그 용도
|
CA3115547A1
(en)
*
|
2018-11-14 |
2020-05-22 |
Jn Biosciences Llc |
Multimeric hybrid fc proteins for replacement of ivig
|
AU2019394940A1
(en)
|
2018-12-05 |
2021-06-24 |
Genentech, Inc. |
Diagnostic methods and compositions for cancer immunotherapy
|
AU2019392711A1
(en)
|
2018-12-05 |
2021-05-20 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
JP2022513198A
(ja)
|
2018-12-10 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
|
US20220064325A1
(en)
|
2018-12-17 |
2022-03-03 |
Alligator Bioscience Ab |
Novel polypeptides
|
EP3898681A2
(en)
|
2018-12-17 |
2021-10-27 |
Alligator Bioscience AB |
Polypeptides
|
TW202035442A
(zh)
|
2018-12-20 |
2020-10-01 |
美商建南德克公司 |
經修飾之抗體Fc及其使用方法
|
TW202039567A
(zh)
|
2018-12-21 |
2020-11-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之促效cd28抗原結合分子
|
TW202030204A
(zh)
|
2018-12-21 |
2020-08-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之超促效cd28抗原結合分子
|
SG11202102859TA
(en)
|
2018-12-21 |
2021-04-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
CA3123503A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Antibody that binds to vegf and il-1beta and methods of use
|
KR20210110827A
(ko)
*
|
2018-12-27 |
2021-09-09 |
킨드레드 바이오사이언시스, 인코포레이티드 |
수의과 용도를 위한 IgG Fc 변이체
|
JP2022518771A
(ja)
*
|
2019-01-22 |
2022-03-16 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
抗原提示好中球由来樹状細胞およびその使用方法
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
AU2020228383A1
(en)
|
2019-02-27 |
2021-09-23 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
|
CN114173875A
(zh)
|
2019-03-01 |
2022-03-11 |
Xencor股份有限公司 |
结合enpp3和cd3的异二聚抗体
|
CA3131104A1
(en)
|
2019-03-06 |
2020-09-10 |
Silverback Therapeutics, Inc. |
Cyclic amino-pyrazinecarboxamide compounds and uses thereof
|
AU2020236015A1
(en)
|
2019-03-14 |
2021-09-09 |
Genentech, Inc. |
Treatment of cancer with HER2XCD3 bispecific antibodies in combination with anti-HER2 MAB
|
MA55285A
(fr)
|
2019-03-14 |
2022-01-19 |
Morphosys Ag |
Anticorps ciblant c5ar
|
JP7301155B2
(ja)
|
2019-04-12 |
2023-06-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
リポカリンムテインを含む二重特異性抗原結合分子
|
AU2020258480A1
(en)
|
2019-04-19 |
2021-10-21 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
BR112021024003A2
(pt)
|
2019-05-31 |
2022-04-19 |
Alx Oncology Inc |
Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
|
WO2020251834A1
(en)
*
|
2019-06-11 |
2020-12-17 |
The Rockefeller University |
Antibodies and methods for treatment of viral infections
|
KR20220035908A
(ko)
|
2019-06-19 |
2022-03-22 |
실버백 테라퓨틱스, 인크. |
항-메소텔린 항체 및 이의 면역접합체
|
BR112021026293A2
(pt)
|
2019-06-26 |
2022-03-03 |
Hoffmann La Roche |
Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula
|
CN114531878A
(zh)
|
2019-06-27 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
新颖icos抗体及包含它们的肿瘤靶向抗原结合分子
|
US20220380478A1
(en)
*
|
2019-07-01 |
2022-12-01 |
Tonix Pharma Holdings Limited |
Anti-cd154 antibodies and uses thereof
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
EP3999115A4
(en)
*
|
2019-07-12 |
2023-11-22 |
LipUm AB |
NEW BSSL ANTIBODIES
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
WO2021011834A1
(en)
|
2019-07-16 |
2021-01-21 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
KR20220028035A
(ko)
|
2019-07-31 |
2022-03-08 |
에프. 호프만-라 로슈 아게 |
Gprc5d에 결합하는 항체
|
CN114667134A
(zh)
|
2019-08-15 |
2022-06-24 |
希沃尔拜克治疗公司 |
苯并氮杂䓬缀合物的制剂及其用途
|
CA3146616A1
(en)
|
2019-09-12 |
2021-03-18 |
Matthew Dominic CASCINO |
Compositions and methods of treating lupus nephritis
|
CA3150999A1
(en)
|
2019-09-18 |
2021-03-25 |
James Thomas Koerber |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
PE20221110A1
(es)
|
2019-09-27 |
2022-07-11 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
WO2021067644A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
US20230165967A1
(en)
|
2019-10-04 |
2023-06-01 |
TAE Life Sciences |
Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties for use in Treating Cancer, Immunological Disorders, and Methods Thereof
|
WO2021072203A1
(en)
|
2019-10-09 |
2021-04-15 |
Silverback Therapeutics, Inc. |
Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
WO2021092171A1
(en)
|
2019-11-06 |
2021-05-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
EP4055046A1
(en)
|
2019-11-06 |
2022-09-14 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
WO2021102332A1
(en)
|
2019-11-22 |
2021-05-27 |
Silverback Therapeutics, Inc. |
Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof
|
KR20220113790A
(ko)
|
2019-12-13 |
2022-08-16 |
제넨테크, 인크. |
항-ly6g6d 항체 및 사용 방법
|
WO2021122875A1
(en)
|
2019-12-18 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a2/mage-a4
|
EP4077363A1
(en)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Il-37 fusion proteins and uses thereof
|
IL292780A
(en)
|
2020-01-09 |
2022-07-01 |
Hoffmann La Roche |
A new 4-1bbl trimer containing antigen-binding molecules
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
BR112022016720A2
(pt)
|
2020-03-06 |
2022-11-16 |
Ona Therapeutics S L |
Anticorpos anti-cd36 e seu uso para tratamento de câncer
|
CA3174103A1
(en)
|
2020-03-06 |
2021-09-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
CA3172111A1
(en)
|
2020-03-19 |
2021-09-23 |
Barbora MALECOVA |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
JPWO2021193870A1
(sl)
*
|
2020-03-26 |
2021-09-30 |
|
|
KR20220159426A
(ko)
|
2020-03-26 |
2022-12-02 |
제넨테크, 인크. |
감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
|
EP4126940A1
(en)
|
2020-03-30 |
2023-02-08 |
F. Hoffmann-La Roche AG |
Antibody that binds to vegf and pdgf-b and methods of use
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
BR112022020629A2
(pt)
|
2020-04-15 |
2022-11-29 |
Hoffmann La Roche |
Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
|
JP2023522972A
(ja)
|
2020-04-22 |
2023-06-01 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
ヘテロ二量体Fc融合タンパク質のための製剤、投薬量レジメン、及び製造工程
|
CR20220576A
(es)
|
2020-05-11 |
2022-12-07 |
Hoffmann La Roche |
Tratamiento conjunto con pbmc modificadas y un inmunoconjugado
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
EP4149964A2
(en)
|
2020-05-15 |
2023-03-22 |
Apogenix AG |
Multi-specific immune modulators
|
EP4153312A1
(en)
|
2020-05-17 |
2023-03-29 |
AstraZeneca UK Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
JP2023504675A
(ja)
|
2020-05-19 |
2023-02-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ガンの処置のための結合分子
|
GB2595299B
(en)
|
2020-05-21 |
2022-08-03 |
Mabsolve Ltd |
Modified immunoglobulin FC regions
|
EP4139002A2
(en)
|
2020-05-22 |
2023-03-01 |
Formycon AG |
Ace2-fc fusion proteins and uses thereof
|
CN115697489A
(zh)
|
2020-06-08 |
2023-02-03 |
豪夫迈·罗氏有限公司 |
抗hbv抗体及其使用方法
|
KR20230024368A
(ko)
|
2020-06-18 |
2023-02-20 |
제넨테크, 인크. |
항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
|
CA3176552A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Immune activating fc domain binding molecules
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
WO2021255142A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
CR20220639A
(es)
|
2020-06-19 |
2023-02-17 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y folr1
|
AU2021291002A1
(en)
|
2020-06-19 |
2022-10-13 |
F. Hoffmann-La Roche Ag |
Protease-activated T cell bispecific antibodies
|
EP4168447A1
(en)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3 and cd19
|
JP2023530760A
(ja)
|
2020-06-23 |
2023-07-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Her2を標的とするアゴニストCD28抗原結合分子
|
KR20230026491A
(ko)
|
2020-06-24 |
2023-02-24 |
제넨테크, 인크. |
아폽토시스 내성 세포주
|
EP4172203A1
(en)
|
2020-06-25 |
2023-05-03 |
F. Hoffmann-La Roche AG |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
CA3184940A1
(en)
|
2020-07-07 |
2022-01-13 |
Jennifer Donglan WU |
Mic antibodies and binding agents and methods of using the same
|
EP4178985A1
(en)
|
2020-07-10 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
MX2023000617A
(es)
|
2020-07-17 |
2023-02-13 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso.
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
JP2023535840A
(ja)
|
2020-07-31 |
2023-08-21 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
EP4188964A1
(en)
|
2020-08-03 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Improved antigen binding receptors
|
AU2021325339A1
(en)
|
2020-08-10 |
2023-04-06 |
Astrazeneca Uk Limited |
SARS-CoV-2 antibodies for treatment and prevention of COVID-19
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
WO2022047222A2
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
JP2023539528A
(ja)
|
2020-09-01 |
2023-09-14 |
メルック・パテント・ゲーエムベーハー |
Nkp30結合体
|
WO2022049165A1
(en)
|
2020-09-04 |
2022-03-10 |
F. Hoffmann-La Roche Ag |
Antibody that binds to vegf-a and ang2 and methods of use
|
KR20230082632A
(ko)
|
2020-10-05 |
2023-06-08 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
|
EP4227413A1
(en)
|
2020-10-07 |
2023-08-16 |
National University Corporation Chiba University |
Novel anti-sugar chain antibody and use thereof
|
IL302029A
(en)
|
2020-10-14 |
2023-06-01 |
Denali Therapeutics Inc |
Fusion proteins containing sulfoglucosamine sulfohydrolase enzymes and methods thereof
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
WO2022090181A1
(en)
|
2020-10-28 |
2022-05-05 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
MX2023004933A
(es)
|
2020-10-29 |
2023-06-06 |
Formycon Ag |
Proteinas de fusion de ace2 y usos de las mismas.
|
WO2022098648A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
JP7402381B2
(ja)
|
2020-11-04 |
2023-12-20 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体による処置のための投与
|
KR20230100732A
(ko)
|
2020-11-04 |
2023-07-05 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이성 항체의 피하 투여
|
CN117916261A
(zh)
|
2020-11-16 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
与靶向fap的cd40激动剂的组合疗法
|
KR20230120665A
(ko)
|
2020-12-17 |
2023-08-17 |
에프. 호프만-라 로슈 아게 |
항-hla-g 항체 및 이의 용도
|
CA3207090A1
(en)
|
2021-01-06 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
AU2022207615A1
(en)
|
2021-01-12 |
2023-07-13 |
F. Hoffmann-La Roche Ag |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
JP2024503654A
(ja)
|
2021-01-13 |
2024-01-26 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
併用療法
|
EP4277931A1
(en)
|
2021-01-13 |
2023-11-22 |
Visterra, Inc. |
Humanized complement 5a receptor 1 antibodies and methods of use thereof
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
CN112980851A
(zh)
*
|
2021-03-03 |
2021-06-18 |
上海奥浦迈生物科技股份有限公司 |
高效检测融合蛋白/抗体Fc段不能介导ADCC和CDC活性的方法
|
EP4301333A2
(en)
|
2021-03-03 |
2024-01-10 |
Formycon AG |
Formulations of ace2 fc fusion proteins
|
WO2022187591A1
(en)
|
2021-03-05 |
2022-09-09 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
WO2022189380A1
(en)
|
2021-03-09 |
2022-09-15 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
AU2022232375A1
(en)
|
2021-03-09 |
2023-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
KR20230156051A
(ko)
|
2021-03-09 |
2023-11-13 |
에프. 호프만-라 로슈 아게 |
Pd-1-표적화 il-2 변이체 면역접합체 및 fap/4-1bb 결합 분자의 병용 요법
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
|
BR112023018621A2
(pt)
|
2021-03-15 |
2023-10-24 |
Hoffmann La Roche |
Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
WO2022207521A1
(en)
|
2021-03-30 |
2022-10-06 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗il-2r抗體及使用方法
|
TW202304524A
(zh)
|
2021-04-10 |
2023-02-01 |
美商普方生物製藥美國公司 |
Folr1結合劑、其結合物及使用方法
|
JP2024514156A
(ja)
*
|
2021-04-14 |
2024-03-28 |
アンジャリウム バイオサイエンシズ エージー |
Fc由来のポリペプチド
|
KR20230173164A
(ko)
|
2021-04-19 |
2023-12-26 |
제넨테크, 인크. |
변형된 포유류 세포
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Cd70結合劑、其結合物及其使用方法
|
CN117321078A
(zh)
|
2021-04-30 |
2023-12-29 |
豪夫迈·罗氏有限公司 |
针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
|
EP4329800A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
US20240228579A1
(en)
|
2021-05-07 |
2024-07-11 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fc mutant with altered binding to fc receptor
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
JP2024521107A
(ja)
|
2021-05-21 |
2024-05-28 |
ジェネンテック, インコーポレイテッド |
目的の組換え産物を産生するための修飾細胞
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
WO2022265331A1
(ko)
*
|
2021-06-14 |
2022-12-22 |
고려대학교 산학협력단 |
제어된 면역 작용 기작과 증가된 혈중 반감기를 갖는 fc변이체들
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
WO2023288182A1
(en)
|
2021-07-12 |
2023-01-19 |
Genentech, Inc. |
Structures for reducing antibody-lipase binding
|
EP4370553A1
(en)
|
2021-07-14 |
2024-05-22 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
AU2022315528A1
(en)
|
2021-07-22 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
EP4377351A1
(en)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer
|
CN118488964A
(zh)
|
2021-07-30 |
2024-08-13 |
Ona疗法有限公司 |
抗cd36抗体及其治疗癌症的用途
|
EP4380980A1
(en)
|
2021-08-03 |
2024-06-12 |
F. Hoffmann-La Roche AG |
Bispecific antibodies and methods of use
|
AU2022324456A1
(en)
|
2021-08-05 |
2024-02-15 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
CN118354789A
(zh)
|
2021-09-03 |
2024-07-16 |
Go医疗股份有限公司 |
抗糖-cMET抗体及其用途
|
KR20240101546A
(ko)
|
2021-09-03 |
2024-07-02 |
고 테라퓨틱스, 인크. |
항-글리코-lamp1 항체 및 그의 용도
|
JPWO2023053282A1
(sl)
|
2021-09-29 |
2023-04-06 |
|
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
CA3234731A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
CA3234966A1
(en)
|
2021-10-14 |
2023-04-20 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
CN118139648A
(zh)
|
2021-10-14 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的替代的PD1-IL7v免疫缀合物
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
WO2023079101A2
(en)
|
2021-11-05 |
2023-05-11 |
Alligator Bioscience Ab |
Novel polypeptides
|
WO2023088876A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
Multi-specific immune modulators
|
CA3236006A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
WO2023094507A1
(en)
|
2021-11-24 |
2023-06-01 |
Formycon Ag |
Improved ace2 fusion proteins
|
KR20240111753A
(ko)
|
2021-11-25 |
2024-07-17 |
에프. 호프만-라 로슈 아게 |
개선된 항원 결합 수용체
|
WO2023094571A1
(en)
|
2021-11-25 |
2023-06-01 |
Formycon Ag |
Stabilization of ace2 fusion proteins
|
WO2023094569A1
(en)
|
2021-11-26 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
MX2024006925A
(es)
|
2021-12-15 |
2024-06-20 |
Genentech Inc |
Polipeptidos de il-18 estabilizados y usos de estos.
|
IL313306A
(en)
|
2021-12-17 |
2024-08-01 |
Viiv Healthcare Co |
Combined treatments for HIV infections and their uses
|
AU2022423749A1
(en)
|
2021-12-20 |
2024-06-13 |
F. Hoffmann-La Roche Ag |
Agonistic ltbr antibodies and bispecific antibodies comprising them
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
WO2023151661A1
(zh)
|
2022-02-11 |
2023-08-17 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Rq生物科技有限公司 |
抗體
|
AR128689A1
(es)
|
2022-03-03 |
2024-06-05 |
Univ Yale |
Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos
|
TW202346365A
(zh)
|
2022-03-23 |
2023-12-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體及化學療法之組合治療
|
WO2023180511A1
(en)
|
2022-03-25 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Improved chimeric receptors
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
TW202404637A
(zh)
|
2022-04-13 |
2024-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法
|
US20230406930A1
(en)
|
2022-04-13 |
2023-12-21 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023212304A1
(en)
|
2022-04-29 |
2023-11-02 |
23Andme, Inc. |
Antigen binding proteins
|
AR129268A1
(es)
|
2022-05-11 |
2024-08-07 |
Hoffmann La Roche |
Anticuerpo que se une a vegf-a e il6 y métodos de uso
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202413433A
(zh)
|
2022-07-19 |
2024-04-01 |
美商建南德克公司 |
用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
|
WO2024020164A2
(en)
|
2022-07-21 |
2024-01-25 |
Firefly Bio, Inc. |
Glucocorticoid receptor agonists and conjugates thereof
|
TW202417504A
(zh)
|
2022-07-22 |
2024-05-01 |
美商建南德克公司 |
抗steap1抗原結合分子及其用途
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
US20240132624A1
(en)
|
2022-07-27 |
2024-04-25 |
Ablynx N.V. |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
WO2024030856A2
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
US12054552B2
(en)
|
2022-09-21 |
2024-08-06 |
Sanofi Biotechnology |
Humanized anti-IL-1R3 antibody and methods of use
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
WO2024077118A2
(en)
|
2022-10-06 |
2024-04-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
TW202421664A
(zh)
|
2022-10-07 |
2024-06-01 |
美商建南德克公司 |
用抗c—c模體趨化因子受體8(ccr8)抗體治療癌症之方法
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Gprc5d tcb及蛋白酶體抑制劑之組合療法
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Gprc5d tcb及cd38抗體之組合療法
|
WO2024083945A1
(en)
|
2022-10-20 |
2024-04-25 |
Glaxosmithkline Intellectual Property (No.3) Limited |
Antigen binding proteins
|
WO2024092038A2
(en)
|
2022-10-25 |
2024-05-02 |
Ablexis, Llc |
Anti-cd3 antibodies
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
WO2024107731A2
(en)
|
2022-11-14 |
2024-05-23 |
Ablexis, Llc |
Anti-pd-l1 antibodies
|
WO2024104933A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules
|
CN116143932A
(zh)
*
|
2022-12-07 |
2023-05-23 |
南开大学 |
一种针对IgE的抗体或其抗原结合片段以及Fc变体
|
EP4386084A1
(en)
|
2022-12-14 |
2024-06-19 |
Formycon AG |
Improved ace2 fusion proteins
|
WO2024127277A1
(en)
|
2022-12-16 |
2024-06-20 |
Glaxosmithkline Intellectual Property Development Limited |
Method of treating pain with an anti-ccl17 antibody
|
EP4431525A1
(en)
|
2023-03-16 |
2024-09-18 |
Anaveon AG |
Il-2 fusion protein
|
WO2024133825A1
(en)
|
2022-12-22 |
2024-06-27 |
Anaveon AG |
Anti-pd-1 antibody antigen-binding domain and immunoconjugate
|
WO2024151515A2
(en)
|
2023-01-09 |
2024-07-18 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
WO2024155807A1
(en)
|
2023-01-18 |
2024-07-25 |
Genentech, Inc. |
Multispecific antibodies and uses thereof
|
WO2024153722A1
(en)
|
2023-01-20 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
US20240294651A1
(en)
|
2023-01-30 |
2024-09-05 |
Kymab Limited |
Antibodies
|
WO2024160736A1
(en)
|
2023-01-30 |
2024-08-08 |
Isar Bioscience Gmbh |
Human anti-trem2 antibody for treating neurodegenerative disorders
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
WO2024163494A1
(en)
|
2023-01-31 |
2024-08-08 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
|
US20240269263A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
WO2024165454A1
(en)
|
2023-02-06 |
2024-08-15 |
F. Hoffmann-La Roche Ag |
Combination therapy and uses thereof
|
WO2024167898A1
(en)
|
2023-02-07 |
2024-08-15 |
Go Therapeutics, Inc. |
ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES
|
WO2024165671A1
(en)
|
2023-02-08 |
2024-08-15 |
Immunos Therapeutics Ag |
FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
|
WO2024170756A1
(en)
|
2023-02-17 |
2024-08-22 |
Ablynx N.V. |
Polypeptides binding to the neonatal fc receptor
|
WO2024178056A1
(en)
|
2023-02-21 |
2024-08-29 |
Teneobio, Inc. |
C-kit binding proteins, chimeric antigen receptors, and uses thereof
|
WO2024184287A1
(en)
|
2023-03-06 |
2024-09-12 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|